First biosimilar monoclonal antibody introduced to clinical praxis: Infliximab;První biosimilární monoklonální protilátka - Infliximab

Klinicka Farmakologie a Farmacie

Volumn 28, Issue 1, 2014, Pages 19-22

  Urbánek, Karel ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

Biosimilar; CT P13; Efficacy; Indications; Infliximab; Safety

Indexed keywords

BIOSIMILAR AGENT; INFLIXIMAB;

ARTICLE; CLINICAL EVALUATION; CLINICAL PRACTICE; DRUG SCREENING; GOVERNMENT; HUMAN;

EID: 84897532848     PISSN: 12127973     EISSN: 18035353     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety and efficacy of CT-P13 and innovator infl iximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013; 72 (10): 1605-1612.
2. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in effi cacy and safetyof CT-P13 compared with innovator infl iximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013; 72 (10): 1613-1620.
3. Yoo DH, Yagensky A, Toncheva A, et al. Impactof CT-P13 and Originator Infl iximab Treatment on Quality of Life Derived from the Health Assessment Questionnaire (HAQ) and Short-form 36 (SF-36) from a Randomized, Double-Blind Trial in Patients with Active RA. Poster na 13th ACR/ARHP Annual Meeting, San Diego 2013. Abstrakt dostupný na http://acrannualmeeting.org/Abstracts.
4. Park W, Miranda P, Brzosko M, et al. Effi cacy and Safety of CT-P13 (infl iximab biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infl iximab to CT-P13. Poster na 13th ACR/ARHP Annual Meeting, San Diego 2013. Abstrakt dostupný na http://acrannualmeeting.org/Abstracts.
5. Yoo DH, Prodanovic N, Jaworski J, et al. Effi cacy and Safety of CT-P13 (Infl iximab biosimilar) over Two Years in Patients with Rheumatoid Arthritis: Comparison Between Continued CT-P13 and Switching from Infl iximab to CT-P13. Přednáška na 13th ACR/ARHP Annual Meeting, San Diego 2013. Abstrakt dostupný na https://ww2.rheumatology.org/apps/MyAnnualMeeting/Abstract/39033.
6. SPC přípravku Remsima. Dostupné na http://www.sukl.cz.